Triple Progress Analysis: Lymphoma Therapeutics, Protein Kinase Inhibitors & Therapeutic Antibodies - Biologics Market Research

Triple Progress Analysis: Lymphoma Therapeutics, Protein Kinase Inhibitors & Therapeutic Antibodies
BioSeeker Group AB
May 29, 2006
322 Pages
Pub ID: BIOS1327668
US $6,210.00 PDF E-mail From Publisher

Abstract
Executive Summary
In this triple analysis report BioSeeker Group has analyzed three major and intertwined areas of cancer R&D, Lymphoma, Protein Kinase Inhibitors and Therapeutic Antibodies, which are all subjects to an extensive number of innovative drug candidates. This extensive 320 pages report compiles and analyzes the progress concerning drug development and competitive situation in the three mentioned key oncology areas. The report will not only provide a framework but also a careful identification and evaluation of drug candidates, technologies and competitors.
Published trial data show an increase in response rates when rituximab is combined with current chemotherapy regimens in both the first- and second- line settings in the treatment of lymphoma. In addition, rituximab show significant off-label usage. Already today it is clear that rituximab has generated substantial revenues for the companies involved in its development. A collection of emerging facts suggest that several of the new targeted therapies under development include agents that cannot just be added into treatment regimens with conventional drugs. A few of them might have isolated properties on certain biologic targets that may require to be modulated in particular ways before or after cytotoxic chemotherapy. Among the emerging therapeutic strategies, passive and active immunotherapies have clearly continued to be leading strategies. Small molecule kinase inhibitors are as well in the forefront.
The commercial and therapeutic success of antibodies will force the industry to look into the next generation of therapeutic antibodies, preparing themselves for the second wave in the lucrative field of therapeutic antibodies. The first-generation formulations of therapeutic antibodies will be facing heavy competition from biogeneric companies as their profitable antibody drugs comes off patent in the future. Among the different strategies (e.g., antibody engineering, changes in primary structure, fusions, chemical modifications glycosylation, pegylation, polymer conjugates), the approach of miniaturizing and delivering antibody drugs is the most promising because it permits better release of active drugs.
The number of protein kinase inhibitor drugs has risen sharply, as the number of targets. The fiercest competition in kinase inhibitor drug development is found in hematological, breast, lung, prostate, and colorectal cancer. Several big pharma companies are out hunting for promising technology and drugs to complement their internal pipeline.
Scope of this report
Status and impact of several novel drugs in development: The lymphoma indication in specific and protein kinase inhibitors and antibodies in oncology in general
Discussion of the challenges in current lymphoma treatment strategies.
Thorough examination of the top cancer therapeutic strategies on the market
Description of the race towards the next generation of therapeutics
Discussion of the challenges in current drug development, including future clinical trials to be made, collaborations and inclusion of novel endpoints.
Competitive landscape assessment
Thorough review of the largest cancer indications.
Drugs according to targets
Targets according to indication
Key reasons to read this report
Gain insight into the current challenges and commercial opportunities in lymphoma treatment in specific and protein kinase inhibitors and antibodies in oncology in general.
One source to the top cancer therapeutic on the market
Key insights into the second wave in the lucrative field of antibody therapeutics and the promising development of protein kinase inhibitors
Competitive landscape assessment, including deals, technologies and drug development.
Assess opportunities and risks for the continued development of innovative developmental treatments
Adopt knowledge from this analysis to drive strategic planning decisions in oncology drug development .